Diabetologie und Stoffwechsel 2025; 20(S 01): S100-S101
DOI: 10.1055/s-0045-1807558
Abstracts | DDG 2025
Poster
Posterwalk 15: Sonstige Themen

Tirzepatide Improved Sleep Disordered Breathing in Adults with Obstructive Sleep Apnea with Obesity: Results from SURMOUNT-OSA Trials.

A Malhotra
1   University of California San Diego, Diabetes and Obesity, La Jolla, CA, United States
,
R R Grunstein
2   Woolcock Institute of Medical Research, Macquarie University and Royal Prince Alfred Hospital and University of Sydney, Diabetes and Obesity, Sydney, Australia
,
I Fietze
3   Centre of Sleep Medicine, Charité University Hospital Berlin, Diabetes and Obesity, Berlin, Germany
,
T E Weaver
4   College of Nursing, University of Illinois Chicago, Chicago, IL, and School of Nursing, University of Pennsylvania, Diabetes and Obesity, Philadelphia, PA, United States
,
J P Dunn
5   Eli Lilly and Company, Diabetes and Obesity, Indianapolis, IN, United States
,
S Chakladar
5   Eli Lilly and Company, Diabetes and Obesity, Indianapolis, IN, United States
,
M C Bunck
5   Eli Lilly and Company, Diabetes and Obesity, Indianapolis, IN, United States
,
J Bednarik
5   Eli Lilly and Company, Diabetes and Obesity, Indianapolis, IN, United States
,
T Hollstein
6   Klinik für Innere Medizin I, Diabetology and Clinical Metabolism Research, Kiel, Germany
› Author Affiliations
› Further Information
Also available ateRef
 

How efficacious and safe was tirzepatide in treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity?

Methodology: SURMOUNT-OSA (NCT05412004) is a master protocol guiding 2 randomized, placebo-controlled trials investigating the efficacy and safety of tirzepatide to placebo in adults living with moderate-to-severe OSA with obesity. Under a master protocol, the two trials were composed of trial 1: included participants who were unable or unwilling to use positive airway pressure (PAP) therapy, and trial 2: included participants who were and planned to stay on PAP therapy during the 52 week duration of the trials. Overall, in the two trials 469 participants were randomized in a 1:1 ratio to receive tirzepatide maximum tolerated dose (MTD) 10 or 15 mg once weekly, or placebo.

Results: At baseline, mean apnea-hypopnea index (AHI) was 50.1 events/hour and mean body mass index was 38.8 kg/m^2. Tirzepatide-treatment was associated with mean AHI reductions from baseline to week 52 of 27.4 (55.0%) and 30.4 (62.8%) events per hour compared to 4.8 (5.0%) and 6.0 (6.4%) events per hour for placebo in trial 1 and trial 2, respectively. Moreover, tirzepatide-treatment was associated with to a mean body weight reduction from baseline of 18.1% and 20.1%, compared to 1.3% and 2.3% for placebo, in trial 1 and trial 2, respectively. The overall safety profile of tirzepatide in SURMOUNT-OSA studies was similar to previously reported SURMOUNT trials. The most commonly reported adverse events in SURMOUNT-OSA trials were gastrointestinal-related and generally mild to moderate in severity and occurred during dose escalation.

Conclusion: Tirzepatide-treatment occurred with clinically meaningfully improved sleep disordered breathing compared to placebo in adults with moderate-to-severe OSA with obesity, with consistent findings across the two trials.

^ denotes square root



Publication History

Article published online:
28 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany